Clinical Trial

Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 5, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A prospective observational cohort study was designed. 1. Comparing of the clinical indicators between the hemolytic group and the non-hemolytic group,such as End-tidal carbon monoxide corrected for ambient CO(ETCOc),direct antiglobulin test(DAT), the highest total serum bilirubin level and hemoglobin. To explore the role of ETCOc in the diagnosis of neonatal ABO hemolytic disease. 2. Comparing of the clinical indicators between the neonates with IVIG treatment and the neonates without IVIG treatment in ABO hemolytic disease, such as ETCOc,total serum bilirubin level before IVIG treatment and ETCOc,total serum bilirubin level after IVIG treatment.To explore the clinical value of ETCOc in the treatment of ABO hemolytic disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-02; most recent amendment 2025-01-31.
Status change: Not Yet Recruiting → Recruiting 2025-01-31
Trial Details
NCT Number NCT05842109
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Conditions ABO Hemolytic Disease of Newborn
Enrollment 112 participants
Start Date 2023-10-31
Primary Completion 2025-10-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-05